BioTime’s CEO Michael West to Speak at GTCbio and Unveil 12 New Diverse Cell Lines to be Launched November 1, 2010
October 14 2010 - 9:00AM
Business Wire
BioTime, Inc. (NYSE Amex:BTIM) announced today that on October
22, 2010 BioTime’s CEO Dr. Michael West will present at the GTCbio
4th Advances in Stem Cell Discovery and Development Conference in
San Francisco, California. Dr. West’s presentation titled: “Fate
Space Screening of Clonal Human ES-derived Embryonic Progenitor
Cell Lines” will include a discussion of the Company’s proprietary
bank of more than 140 diverse human cell types made from human
embryonic stem cells, the company’s screening technology for
discovering means of manufacturing human cell types, and the
potential use of these cells for diverse new therapeutics and drug
discovery. During his lecture, Dr. West will unveil 12 new lines
that will be launched beginning November 1, 2010. Additional
information about these new products will be found at:
http://www.embryome.com beginning with product launch. Dr. West’s
presentation will be available on BioTime’s website at
www.biotimeinc.com.
The annual GTCbio Stem Cell Research & Therapeutics
Conference provides information regarding cutting-edge developments
in all areas of stem cell research including the biology, medicine,
applications, regulations, and business of stem cells. This year’s
conference will address recent developments in pre-clinical and
clinical trials of stem cell therapy, regenerative medicine and
tissue engineering, cancer stem cells, stem cell reprogramming, FDA
and NIH policies regarding funding for stem cell research, and
private funding from the pharmaceutical industry.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a
biotechnology company focused on regenerative medicine and blood
plasma volume expanders. Its broad platform of stem cell
technologies is developed through subsidiaries focused on specific
fields of applications. BioTime develops and markets research
products in the field of stem cells and regenerative medicine
through its wholly owned subsidiary Embryome Sciences, Inc.
BioTime’s therapeutic product development strategy is pursued
through subsidiaries that focus on specific organ systems and
related diseases for which there is a high unmet medical need.
BioTime’s majority owned subsidiary Cell Cure Neurosciences, Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic
applications of stem cells to treat orthopedic diseases and
injuries. Another subsidiary, OncoCyte Corporation, focuses on the
therapeutic applications of stem cell technology in cancer.
BioTime’s Singapore subsidiary, ES Cell International Pte Ltd, has
been at the forefront of advances in human embryonic stem (“hES”)
cell technology, having been one of the earliest distributors of
hES cell lines to the research community. ESI has produced
clinical-grade human embryonic stem cell lines that were derived
following principles of good manufacturing practice and currently
offers them for potential use in therapeutic product development.
In addition to its stem cell products, BioTime develops blood
plasma volume expanders, blood replacement solutions for
hypothermic (low temperature) surgery, and technology for use in
surgery, emergency trauma treatment and other applications.
BioTime’s lead product, Hextend®, is a blood plasma volume expander
manufactured and distributed in the U.S. by Hospira, Inc. and in
South Korea by CJ CheilJedang Corp. under exclusive licensing
agreements. Additional information about BioTime, Embryome
Sciences, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, and ESI can
be found on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for the company and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the company’s business,
particularly those mentioned in the cautionary statements found in
the company’s Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0